Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

3033 Background: AZD7762, a potent Chk1/Chk2 inhibitor, has shown synergistic activity with irino in xenograft models. Methods: A 3+3 design evaluated the safety and PK of AZD7762 (6–144 mg iv) ± irino (100 or 125 mg/m2 iv) (NCT00473616). AZD7762 was given alone on days 1 and 8 (Cycle 0); after 7 days’ observation, AZD7762 was given after irino on days 1 and 8 of 21-day cycles until disease progression/discontinuation for any reason. To further...